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ABSTRACT 
Survivorship statistics demonstrate that the incidence of cancer continues to rise worldwide, 
with a further 60% increase in diagnoses predicted by 2030 attributed to lifestyle risk factors, 
screening programmes resulting in earlier diagnosis but also the changing demographics of 
the population.  More than a third of new cancer diagnoses and almost half of cancer 
survivors are now aged 70 years or older. Despite this increasing incidence, worldwide 5-year 
cancer survival rates have improved significantly over the past two decades. After cancer, 
cardiovascular disease is the second most common cause of death in developed countries.  
With continued improvements in overall prognosis, cancer patients have an increased 
exposure to cardiovascular risk factors resulting in higher cardiovascular morbidity and 
mortality, particularly in older patients. This relationship between cancer and cardiovascular 
disease is not surprising as they share the common risk factors of aging, smoking, obesity, and 
poor diet. In this review, we discuss the toxicity of cancer treatments on the cardiovascular 
system, particularly in older patients. We focus primarily on radiotherapy and anthracycline 
chemotherapy because of their chronic adverse effects and appraise approaches toward the 
detection and treatment of this toxicity to maximise survival and quality of life of older 
patients with cancer. 
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1. INTRODUCTION 
Older patients with cancer present specific opportunities and risks for cancer treatment as 
the have high absolute risks and a high prevalence of risk factors and co-morbidity1. In breast 
cancer, where over a third of diagnoses are made in women over seventy years of age, the 
prevalence of cardiovascular co-morbidity and frailty is particularly high, and deaths from 
other causes (including cardiovascular disease) exceed breast cancer mortality2, 3. The risks of 
surgery, radiotherapy and chemotherapy are also increased in this population3-6. In multiple 
myeloma, where the median age at diagnosis is 75 years, there is a high prevalence of 
hypertension and other cardiovascular co-morbidities7, while in prostate cancer, with a peak 
incidence in men over the age of 75 years, the existence of cardiovascular disease directly 
affects treatment regimens8. As a direct result of this, cancer patients over 65 years have the 
highest mortality rates9, but they remain under-represented in clinical trials10, 11. Combined 
with the underutilisation of cardiovascular prevention in older patients12 this results in the 
underestimation of their risk of cardiovascular adverse events10, 11.  Cancer treatment can 
have significant ‘off-target’ effects on the cardiovascular system. Acute toxicity, such as 
dysrhythmias, hyper- and hypotension during or shortly after administration, are usually easy 
to identify and manage. 13-15 Late effects however present a different challenge because they 
are irreversible and require active screening for early detection. Cardiomyopathy, pericardial 
disease, atrial fibrillation, vascular disease and heart failure can all have significant impacts 
on quality of life and mortality. Proactive prevention, detection and treatment are required 
to minimise their impact on older cancer patients. 
In this review, we discuss the toxicity of cancer treatments on the cardiovascular 
system, particularly in older patients, and identify practical prevention and treatment 
strategies. We focus primarily on radiotherapy and anthracycline chemotherapy because of 
their chronic adverse effects, but also review other cancer treatments associated with 
significant cardiovascular toxicity. 
 
2. RADIOTHERAPY 
Radiotherapy significantly reduces breast cancer recurrence in appropriate patients, but it is 
recognised as a cardiovascular risk factor, with mediastinal radiation of the coronary arteries 
and myocardium resulting in an increased risk of coronary artery stenoses and myocardial 
fibrosis. Even at low radiotherapy doses, endothelial function can be affected and diffuse 
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inflammation of the coronary arteries can result in interstitial fibrosis and microvascular 
injury16. Whilst these cellular changes are predominantly recognised as atherosclerotic 
manifestations, the diffuse fibrosis has been shown to originate from an acute inflammatory 
reaction.17 If an extensive area of healthy myocardial tissue is replaced by fibrotic tissue, 
chronic cardiac failure may ensue.18  To reduce the radiation exposure to surrounding healthy 
tissue, radiotherapy regimens have changed significantly over the last 30 years, especially 
with the development of 3-dimensional Conformal Radiation which also maximises therapy 
to the tumour.  
In the treatment of breast cancer patients, myocardial exposure to ionising radiation 
has been shown to increase the rate of ischaemic heart disease in studies comparing the 
relative risks of left and right sided irradiation.  Jacob et al. reported left breast treated 
patients experienced higher rates of coronary events compared to patients irradiated for right 
breast cancer, with a relative risk increase between 1.2 and 3.519.  Similar conclusions were 
reached by Derby et al. who estimated the mean dose of cardiac radiation in left-sided breast 
cancer to be 6.6 Gray(Gy), compared to 2.9Gy for those with right-sided tumours.  This 
resulted in higher rates of major coronary events in patients with left-sided (56.4%) compared 
to right-sided breast cancer (43.6%; P<0.002).  The relationship between risk of a major 
coronary event and mean dose of radiation to the heart was found to be linear, with the rate 
of coronary events increasing by 7.4% for each increase of 1Gy in mean radiation dose 
delivered to the heart (95% CI, 2.9 to 14.5; P<0.001) 20. 
Although the absolute risk of radiotherapy-induced cardiotoxicity is low in the short 
term, the presence of cardiac risk factors and pre-existing coronary artery disease significantly 
increases this risk.  Most patient study cohorts include predominantly younger patients, 
however Doyle et al. studied women older than 65 years with stages I to III breast cancer21.  
To ensure they calculated just the effects of radiotherapy on major cardiovascular events, 
their methodology included statistical adjustment for cardiac risk factors and pre-existing 
cardiac disease.  They found no significant difference in cardiac morbidity and mortality after 
radiotherapy for early stages of breast cancer in older patients (radiotherapy hazard ratio (HR) 
for myocardial infarction 0.93)21.  However the oldest patients (>85 years) were less likely to 
receive radiotherapy treatment (17.3%) than patients in the 65-69 years-cohort (55.8%)20, 21. 
Future studies need to include larger cohorts of older patients to inform treatment choices in 
this increasing large population of cancer patients. 
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Research evaluating the combined cardiotoxic effects of radiotherapy and 
anthracycline chemotherapy remains limited, primarily due to the differing mechanisms of 
myocardial injury between these therapies, both culminating in cardiac failure.22 
Furthermore, long-term cohort studies may predicate doxorubicin therapy, whilst exclusion 
criteria preclude patients with pre-existing cardiac disease from being enrolled.22, 23  
Lee Jones et al, describe a ‘multiple-hit’ hypothesis which recognises the cumulative 
impact of adjuvant therapy incurred upon cardiomyocytes during treatment.  Cardiac injury 
sustained from either radiotherapy or systemic chemotherapy enhances patients’ 
susceptibility to further cellular damage.24 These long-term effects has been demonstrated 
studies of patients receiving anthracycline therapy and combined radiotherapy treatment.  
Whilst the overall numbers are small, the data available demonstrates patients are at an 
increased risk of developing cardiac failure and cardiomyopathy.25, 26 
 
The European Association of Cardiovascular Imaging and the American Society of 
Echocardiography expert groups have therefore provided guidelines for radiation-induced 
cardiotoxicity, but many of these recommendations are not supported by randomised 
controlled trial data and need to be interpreted in the context of absolute risk and benefit 27, 
28. The recommendations include screening patients for cardiovascular risk factors prior to 
radiotherapy, with those at highest cardiovascular risk, which includes prior exposure to 
anthracycline therapy, being considered for modified radiotherapy or an alternative 
treatment strategy.  An alternative strategy would be to assess underlying cardiovascular risk 
with an established risk prediction model and then reduce that risk with evidence-based 
treatments such as statins or anti-hypertensive therapy29-31.    
 
3. CARDIOTOXICITY ASSOCIATED WITH ANTHRACYCLINE TREATMENT 
Cardiotoxicities caused by cancer therapy have been well described and are recognised in 
both oncology and cardiology clinical practice guidelines32, 33.  Anthracycline chemotherapy 
remains one of the most widely used cancer treatments with proven efficacy across a wide 
range of solid tumours and haematological malignancies including breast cancer, sarcoma, 
lymphoma and leukaemia.  Despite clear anti-tumour efficacy, anthracycline therapy is 
recognised to result in a range of adverse cardiovascular effects34,35.  Anthracycline cardiac 
toxicity ranges from subclinical myocardial injury to fulminant symptomatic left ventricular 
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systolic failure.  Toxicity is described as either acute (<1% incidence), early-onset chronic 
progressive (1.6-2.1% of patients) defined as during therapy and within the first year post-
treatment, or late-onset chronic progressive (up to 5% incidence) which arises at least one 
year after chemotherapy32, 34, 36. In the case of chronic cardiovascular toxicity, this can remain 
undetected until decades after the first dose36, 37. The major risk factor for anthracycline-
induced chronic cardiovascular toxicity is the cumulative drug exposure34, 37. The incidence of 
clinical heart failure with doxorubicin treatment rises exponentially from 5% at a cumulative 
dose of 400 mg/m2 to 48% at 700 mg/m2 33. Reported rates of cardiotoxicity with lower doses 
vary widely because of different patient populations with varying periods of follow-up, 
different definitions of cardiotoxicity and different screening strategies. This risk is increased 
in older patients or when delivered as a combination therapeutic regimen35, 38, 39, and it is 
clear that cardiomyopathy can be seen many years after anthracycline treatment, even when 
low doses have been used.40 
There are several hypotheses for the mechanism(s) by which anthracyclines induce 
cardiovascular toxicity, including effects on cardiomyocyte mitochondrial function and energy 
balance, modulation of cellular and mitochondrial topoisomerase functionality, induction of 
oxidative stress with free radical formation, and impaired calcium signalling affecting 
myocardial relaxation41, 42. Anthracycline-induced oxidative stress occurs through iron-
mediated generation of reactive free radicals,43 resulting in markedly higher mitochondrial 
iron levels in cardiac tissue from patients with anthracycline-induced cardiomyopathy than 
other cardiomyopathies44. Co-administration of the iron-chelating agent dexrazoxane has 
been shown to decrease tissue damage, reduce the risk of left ventricular dysfunction, and 
the risk of cardiac failure45, 46. Dexrazoxane is included in European and American clinical 
practice guidelines and treatment protocols as a cardio-protective agent for anthracycline 
therapy, 45, 47. 
While these mechanisms can explain the acute apoptosis of cardiac myocytes seen in 
anthracycline toxicity, further explanation is required for the frequently long sub-clinical 
period seen before clinical heart failure is evident.  In susceptible individuals, anthracycline 
exposure induces cardiac myocyte and progenitor cell apoptosis. In most cases, this loss of 
cardiac myocytes is well compensated by increase in cell volume48 and there is no measurable 
reduction myocardial mass or function. However, as part of the normal aging process, over 
50 million cardiac myocytes are lost each year, so over time, particularly when associated with 
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cardiovascular stress such as the development of hypertension, decompensation and clinical 
heart failure can occur. In older cancer patients, cardiac reserve is already reduced at the 
point of anthracycline exposure and therefore heart failure is more common at lower 
anthracycline doses1, 34, 48. 
Age-related changes in drug pharmacokinetics also have a significant effect on the 
cardiotoxic effects of chemotherapy49. The initial blood plasma concentration of 
anthracyclines is higher in older patients due to a reduced rate of distribution into other body 
compartments, a consequence of altered regional blood flow49. Furthermore, an inverse 
correlation between age and anthracycline clearance has been described, showing a 
significant 9% reduction in clearance per decade age increase49. In addition, as anthracyclines 
are highly protein bound, the low serum albumin levels common in older patients, can 
significantly increase systemic free drug levels. Myocardial anthracycline exposure is 
therefore higher in older patients who then have an increased risk of drug-induced toxicity. It 
is important to recognise age-related differences in anthracycline effects alongside a patient’s 
co-morbidities in the risk-benefit analysis of anthracycline treatment in older patients. 
Risk factors for the development of anthracycline toxicity have been proposed - greater 
cumulative anthracycline dose, shorter duration of intravenous infusion, female gender, 
extremes of age, associated mediastinal radiotherapy and longer duration of survival36.  The 
delivery of anthracyclines as a prolonged infusion rather than a bolus has been investigated 
as a potential cardiovascular protection strategy45. Although there is evidence of reduced 
acute cardiac toxicity50 long-term studies have been disappointing 51-53 and this strategy is not 
widely used. Liposomal formulations reduce the exposure of the cardiovascular system to 
anthracycline and thus reduce cardiac damage49, 50. These formulations have equivalent 
efficacy to standard regimens and are used in some children as well as older patients but the 
increased cost has limited their use 54, 55. 
Through extrapolation of these known factors, prediction models estimating the 
probability of developing congestive cardiac failure, ischaemic heart disease and stroke have 
been calculated56. By combining genetic analysis with clinical factors, Armenian et al. have 
established a risk prediction model which correctly identified 75% of patients in the high-risk 
group who went on to develop anthracycline cardiotoxicity, whereas in the low risk group 
96% of patients did not develop cardiotoxicity56.  These models are validated in survivors of 
childhood cancers, but accurate risk prediction for the older adult population is still being 
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explored in order to refine cardiomyopathy surveillance and reduce anthracycline-related 
morbidity57. 
 
3.1. DETECTION OF ANTHRACYCLINE TOXICITY IN THE CLINIC: IMAGING 
The significant morbidity and mortality associated with chemotherapy-induced 
cardiovascular toxicity makes early identification and management of chemotherapeutic 
cardiac injury very important to improve cancer patients’ overall survival and quality of life. 
Patients with early stages of cardiotoxicity are often asymptomatic, so identifying high-risk 
patients who are most likely to develop progressive cardiovascular disease is essential. This 
will require a combination of imaging studies and biomarkers to guide the timely initiation of 
treatment strategies58. Detection of cardiovascular dysfunction is most commonly achieved 
by serial monitoring of cardiac left ventricular ejection fraction (LVEF) using multi-gated 
acquisition (MUGA) or echocardiogram (ECHO), with cardiac magnetic resonance imaging 
(MRI) reserved for patients with suboptimal echo imaging. The International Imaging 
consensus and European Society of Cardiology position paper defines cardiotoxicity as a 
reduction in LVEF of ≥10% from baseline to a value of <50%.33  Although LVEF is a useful 
measure of load-dependent left ventricular function and has been shown to correlate with 
mortality, it is not equivalent to heart failure (HF), which is a clinical syndrome of symptoms 
and physical signs. Reduced LVEF is best characterised as a ‘biomarker’ associated with HF59. 
International guidelines recommend a baseline assessment of left ventricular systolic function 
together with global longitudinal strain to establish cardiac function prior to chemotherapy.  
Clinical practice recommendations for cardiotoxicity monitoring have been proposed but 
there is limited evidence to support the optimal timing of screening or its frequency. 
Curigliano et al. proposed cardiac functional screening at 6 months following anthracycline 
chemotherapy, annually for 2 to 3 years before continuing at 3 to 5 year intervals32. High risk 
patients, defined by anthracycline dose, extremes of age and cardiovascular risk factors, 
would be screened more frequently, particularly during the first 12 months after 
chemotherapy32. Because of the high costs and burden to patients, post-anthracycline 
screening strategies require further investigation, including cost-effectiveness analysis, 
before they will be widely adopted in clinical practice, particularly for older patients11. 
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3.2. DETECTION OF ANTHRACYCLINE TOXICITY IN THE CLINIC: BIOMARKERS 
One of the problems with the detection of anthracycline toxicity is that changes in myocardial 
function are a late sign, and may not be present until months or years after the loss of cardiac 
myocytes because of the heart’s ability to remodel. Blood biomarkers can identify toxicity 
during chemotherapy therapy, allowing early cardio-protective treatment or even potentially 
a change in cytotoxic regimen. Cardiac troponin is released by myocyte necrosis and is both 
highly sensitive and specific while chronic increases in natriuretic peptides indicate ventricular 
wall stress so are a later and less specific indication of cardiac toxicity60.  After anthracycline 
chemotherapy, patients with troponin-I release were shown to be at increased risk of 
cardiotoxicity and left ventricular systolic impairment. Persistent troponin elevation a month 
after the last chemotherapy dose is associated with an 85% probability of a major cardiac 
event within 12 months60. These patients can be offered appropriate early pharmacological 
intervention and be closely monitored. Serial negative troponin measurements identified 
patients at a lower risk of cardiac events (negative predictive value 99%) who may require 
less monitoring. Natriuretic peptides (ANP, BNP and NT-proBNP) are released from the 
myocardium in response to increased wall tension and pressure overload which is associated 
with ventricular dysfunction 61, 62.  Patients with persistently elevated NT-proBNP after 
chemotherapy are at increased risk of cardiac dysfunction61-63 but low sensitivity and 
specificity limits its usefulness in routine clinical practice. 
 
4. UNDERLYING CARDIOVASCULAR RISK 
In addition to addressing the specific cardiovascular risks of cancer treatment, it is important 
to consider underlying cardiovascular risk because coronary artery disease and stroke are the 
second most common cause of death in cancer patients. Risk factors and previous 
cardiovascular events are very common in older people and are associated with significant 
morbidity and mortality 64. A study of 100 consecutive men with localised prostate cancer at 
a mean age of 73 years, found that 25% had pre-existing vascular disease and an additional 
74% had risk factors putting them in the high or intermediate Framingham risk categories 
while only 26% were receiving primary prevention treatment with statins12.  This is 
particularly important as meta-analyses have shown statin treatment to reduce both 
prostate-specific and all-cause mortality by 24% 65.  
11 
 
Regular exercise is known to reduce cardiovascular events and the development of co-
morbidities such as diabetes mellitus, hypertension and hyperlipidaemia.  Jones et al. 
investigated the association between exercise and risk of cardiovascular events in adult 
survivors of Hodgkin’s lymphoma66.  With a median follow-up of 11.9 years, there was a 51% 
reduction in cardiovascular events in patients who met the American vigorous-intensity 
exercise guidelines (i.e. >9 metabolic equivalent hours per week)66. Whilst it is unrealistic to 
expect all elderly patients to attain these exercise levels, aerobic training improves myocardial 
contractility, diastolic relaxation and filling, increases stroke volume and attenuates 
pathological left ventricular remodelling.67  Studies evaluating the benefits of ‘pre-
habilitation’, the promotion of physical and psychological well-being from the time of 
diagnosis to commencing oncology treatment, have demonstrated reductions in hospital stay 
and improved outcomes after surgery67-69.  Encouraging cancer survivors to undertake regular 
exercise may help to prevent or delay treatment-associated cardiovascular toxicity whilst 
simultaneously reducing underlying cardiovascular risk66, 68.  
Particularly in older patients, high baseline cardiovascular risk significantly increases 
the risk of cardiotoxicity, and screening to facilitate modification of these risk factors prior to 
initiation of therapy is recommended to improve cardiovascular outcomes.  Patients’ risk can 
be quantified using an evidence-based score (HeartScore, QRISK-3 or 2013 ACC/AHA guideline 
on the assessment of cardiovascular risk) and then those at increased risk can be offered 
appropriate preventative lifestyle advice and treatments 70-72. 
While overall cancer survival continues to improve73, 74, analysis of the Childhood 
Cancer Survivor Study (CCSS) has shown that 15-25 years after diagnosis and treatment, 
survivors have an 8-fold increased rate of cardiac death compared age and sex matched 
controls (heart failure 15-fold increase, cardiovascular disease 10-fold increase, stroke 9-fold 
increase)56, 75.  Sibling studies have shown increased cardiovascular risk in cancer survivors - 
hypertension 40.2% vs. 25.5% (p<0.01) and hyperlipidaemia 23.0% vs. 13.6% (p<0.008)56, 76 
and that this is associated with increased cardiac mortality.  Thoracic-radiation exposure is 
also associated with an increase in cardiovascular risk factors including obesity, dyslipidaemia, 
hypertension and diabetes mellitus77, 78. 
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5. CONCLUSIONS 
As cancer treatment has become increasingly successful at improving cancer-specific and 
overall survival, it has become progressively more important that cardiovascular risks are 
assessed and proactively managed. Early diagnosis and appropriate management of 
established cardiovascular risk factors such as hypertension, diabetes, dyslipidaemia, smoking 
and obesity are recommended for all cancer patients and is most important in older people 
because of their higher absolute risk. Evidence-based interventions such as lowering blood 
pressure, good glycaemic control, statin therapy, smoking cessation, cardiovascular exercise 
and weight reduction should be offered to all appropriate patients who should be treated in 
accordance with published national and international guidelines.  
Many cancer treatments are associated with cardiovascular toxicity, but it is difficult 
to determine the magnitude of that risk for an individual patient with currently available data. 
The best evidence exists for anthracyclines and radiotherapy where patient and treatment 
related information is used in the risk-benefit analysis prior to commencing cancer treatment, 
in some cases selecting therapy with a lower cardiovascular toxicity profile. It is important 
that we use the information we have now to identify and treat each patient’s underlying 
cardiovascular risk, and to assess the long-term cardiovascular risks associated their cancer 
treatment so that we can take a proactive approach to the detection and treatment of toxicity 
and maximise older patients’ survival and quality of life. 
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Recommendations for reducing cardiovascular risk in older cancer patients: 
 
All patients should be offered appropriate lifestyle advice to reduce their cardiovascular risk in collaboration 
with their primary care physician: 
• smoking cessation 
• cardio-protective diet 
• physical activity 
• weight management 
• alcohol consumption 
 
Secondary Prevention 
All patients with a history of established cardiovascular disease (angina, acute coronary syndromes, stroke, 
transient ischaemic attack or peripheral vascular disease) should undergo evidence-based investigation 
under the care of a specialist and be offered secondary prevention treatment as recommended in national 
and international guidelines. 
Primary Prevention: 
Cancer patients without a history of a vascular event, should have their cardiovascular risk assessed using an 
established scoring system (QRISK®3, qrisk.org/three/; HeartScore, www.heartscore.org; JBS3, 
www.jbs3risk.com; or ACCC/AHA CVD risk calculator, www.cvriskcalculator.com).  
Thresholds for pharmacological treatment vary between countries70-72,but there is clinical and cost-
effectiveness evidence for statin treatment using atorvastatin 20mg daily in all patients with a 10-year 
cardiovascular risk of 10% or greater71. 
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